Elaine Griffin
Family Medicine · Greensboro, NCNPI 1700955671
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 185 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $799 and has fallen 96.8% since, to $26 in 2025.
Across 185 payments — averaging $15.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$413
- Amgen$312
- AstraZeneca$253
- AbbVie$224
- Abbott$201
- Lilly USA, LLC$182
- plus $1K from 24 others
What the payments were for
- Consulting fees$1505%
- Food & beverage$2,74495%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 37 | $413 |
| Amgen | 27 | $312 |
| AstraZeneca | 12 | $253 |
| AbbVie(2 entities) | 13 | $224 |
| Abbott | 9 | $201 |
| Lilly USA, LLC | 12 | $182 |
| Boehringer Ingelheim | 11 | $178 |
| Comsort, Inc | 1 | $150 |
| GSK | 7 | $113 |
| Sanofi-aventis U.S. LLC | 7 | $105 |
| Amarin Pharma, Inc. | 6 | $89 |
| Merck | 6 | $78 |
| Astellas Pharma US Inc | 5 | $64 |
| Xeris Pharmaceuticals, Inc. | 4 | $64 |
| Pfizer | 4 | $58 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $55 |
| Paratek Pharmaceuticals, Inc. | 2 | $47 |
| Johnson & Johnson | 3 | $43 |
| Novartis | 2 | $34 |
| Bayer | 2 | $31 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Dermira, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Shield Therapeutics Inc | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Gilead | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GARDASIL$150
How this compares
$2,894 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lamotrigine | 12 | $586 |
| Memantine Hcl | 12 | $454 |
| Donepezil Hcl | 12 | $266 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Greensboro
- Veita BlandGreensboro$51K
- William CromwellRaleigh$879K
- Steve VacalisGastonia$693K
- David DundeeWinston Salem$633K
- Kevin SodenCharlotte$558K
- Brian ForrestApex$398K
- Joseph KonenCharlotte$322K
- Richard RachimaCharlotte$294K
- Dimitrios HondrosCharlotte$275K
- Domingo Rodriguez-CueGarner$253K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.